Flagship explainer
What drives Ultragenyx Pharmaceutical Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$575M | FY2025 |
| |
| Income before tax | −$571M | FY2025 |
|
| Operating income | −$535M | FY2025 |
|
| $673M | FY2025 |
| |
| Ending assets | $1.5B | FY2025 |
|
| Beginning assets | $1.5B | FY2024 |
|
| −$80M | FY2025 |
| |
| $255M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001193125-26-057329